GNPX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	30 273.00
Average Volume	89 120.00
Market Cap	4.41M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-2.54 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0380 (1.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-18	Berger Mark Stanley	Sell	1 319	Common Stock
2024-02-18	Varner John Rodney	Sell	2 642	Common Stock
2024-02-18	Confer Ryan M.	Sell	1 126	Common Stock
2023-06-27	Moreno Toscano Jose Antonio	Buy	123 795	Common Stock
2023-06-27	Longnecker Brent M	Buy	123 795	Common Stock

INSIDER POWER
95.58
Last 87 transactions
Buy: 12 465 411 \| Sell: 3 375 631

Genprex Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genprex Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-15 004.00 (0.00 %)
EPS:	$-22.56

Q4	2023
Revenue:	$0
Gross Profit:	$-3 426.00 (0.00 %)
EPS:	$-3.99

Q3	2023
Revenue:	$0
Gross Profit:	$-3 724.00 (0.00 %)
EPS:	$-5.36

Q2	2023
Revenue:	$0
Gross Profit:	$-3 837.00 (0.00 %)
EPS:	$-6.14

Financial Reports:

No articles found.

Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.